DDInter1164 DDInter704
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Metformin {u} (Compound) upregulates {v} (Gene) SLC25A4
SLC25A4 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Metformin {u} (Compound) downregulates {v} (Gene) NOSIP
NOSIP {u} (Gene) is upregulated by {v} (Compound) Everolimus
Metformin {u} (Compound) downregulates {v} (Gene) TXNDC9
TXNDC9 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Metformin {u} (Compound) binds {v} (Gene) NDUFA9
NDUFA9 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Metformin {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Metformin {u} (Compound) upregulates {v} (Gene) SLC25A4
SLC25A4 {u} (Gene) regulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Metformin {u} (Compound) upregulates {v} (Gene) WDR7
WDR7 {u} (Gene) is regulated by {v} (Gene) PNP
PNP {u} (Gene) is upregulated by {v} (Compound) Everolimus
Metformin {u} (Compound) downregulates {v} (Gene) NOSIP
NOSIP {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Metformin (Compound) upregulates SLC25A4 (Gene) and SLC25A4 (Gene) is upregulated by Everolimus (Compound)
Metformin (Compound) downregulates NOSIP (Gene) and NOSIP (Gene) is upregulated by Everolimus (Compound)
Metformin (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Everolimus (Compound)
Metformin (Compound) binds NDUFA9 (Gene) and NDUFA9 (Gene) is downregulated by Everolimus (Compound)
Metformin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Everolimus (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Metformin (Compound) upregulates SLC25A4 (Gene) and SLC25A4 (Gene) regulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Everolimus (Compound)
Metformin (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is regulated by PNP (Gene) and PNP (Gene) is upregulated by Everolimus (Compound)
Metformin (Compound) downregulates NOSIP (Gene) and NOSIP (Gene) is downregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)